<DOC>
	<DOC>NCT01180465</DOC>
	<brief_summary>LIPO-102 is under evaluation for treatment of abdominal adiposity</brief_summary>
	<brief_title>A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>18 50 years old inclusive Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the PPNS or CPNS BMI &lt; 25kg/m sq Stable diet and exercise and body weight Prior treatment of abdominal subcutaneous adipose tissue Females within 12 months postpardum Known hypersensitivity to the drugs or components</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Treatment of abdominal adiposity</keyword>
</DOC>